Truist raises Zymeworks stock price target on pipeline progress

Truist Securities raised its price target for Zymeworks Inc. (NASDAQ:ZYME) to $35, citing pipeline progress and partnerships. The stock is up 53.6% over the past year, with a consensus Buy rating and 46% upside potential. Zymeworks recently acquired Theravance Biopharma and partnered with Roche for ZW209, with analysts highlighting positive developments and raising price targets.

Original reporting
Published Oct 27, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 6:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ZYME
Bullish
high confidence
Mentioned
$ZYME
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZYMEBullishMed
01

Why it matters

Analyst price target increase and deal announcements provide fresh bullish catalyst for ZYME.

02

Market read

Analyst upgrades and strategic deals could drive ZYME higher in the short term.

03

What to watch

Potential dilution from future financing rounds and regulatory timelines for the Roche partnership.

Relevance 7/10Novelty 6/10Timing: today

Background

Truist Securities updated its valuation on Zymeworks after the company closed its Theravance Biopharma acquisition and announced a Roche licensing deal.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Truist raised its price target on Zymeworks to $35 and highlighted its recent acquisition of Theravance and Roche partnership.

Expected impact

potential upside as investors price in higher target and deal synergies

Evidence & confidence

The price target lift and disclosed $55M upfront payment plus acquisition cash‑flow benefits provide fresh bullish catalyst.

Market effects

Positive signal for biotech sector as partner‑funded development model gains analyst support.

North American biotech equities may see modest lift.

Limited to investors tracking US‑listed biotech stocks.

Counterpoint

The acquisition integration risk and still‑developing durability data could temper upside.

Key entities

  • Zymeworks Inc.

    Biotech firm developing trispecific T‑cell engagers.

  • Roche

    Partner in licensing agreement for ZW209.

  • Theravance Biopharma

    Acquired by Zymeworks to expand commercial and royalty streams.

Related articles

$ZYMEMed

Zymeworks Authorized To Buy Back Up To $200 Mln Of Shares

Zymeworks' board approved a $200M share buyback program, starting before 2026 and ending in 2028, funded by cash reserves and expected inflows, including Roche fees and a potential milestone payment. The company completed a $125M buyback earlier this year. Shares closed at $26.24 on Friday.

$ZYMEHighAI 9/10

Zymeworks Inc. (ZYME): Reports Third Quarter 2026 Financial Results

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results • 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 m

$ZYMEMedAI 8/10

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.

$ZYMEMedAI 9/10

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

Zymeworks presented updated trial results for ZW191, an ovarian cancer treatment, showing 65% and 55% response rates at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company plans to seek external funding for further development. Zymeworks also highlighted positive data from a partner's study of Ziihera in gastroesophageal cancer. Management discussed strategic plans for R&D, partnerships, and capital allocation.